TY - JOUR
T1 - EGFR mutation testing practices within the Asia pacific region
T2 - Results of a multicenter diagnostic survey
AU - Yatabe, Yasushi
AU - Kerr, Keith M.
AU - Utomo, Ahmad
AU - Rajadurai, Pathmanathan
AU - Tran, Van Khanh
AU - Du, Xiang
AU - Chou, Teh Ying
AU - Enriquez, Ma Luisa D.
AU - Lee, Geon Kook
AU - Iqbal, Jabed
AU - Shuangshoti, Shanop
AU - Chung, Jin Haeng
AU - Hagiwara, Koichi
AU - Liang, Zhiyong
AU - Normanno, Nicola
AU - Park, Keunchil
AU - Toyooka, Shinichi
AU - Tsai, Chun Ming
AU - Waring, Paul
AU - Zhang, Li
AU - Mccormack, Rose
AU - Ratcliffe, Marianne
AU - Itoh, Yohji
AU - Sugeno, Masatoshi
AU - Mok, Tony
N1 - Publisher Copyright:
© 2014 by the International Association for the Study of Lung Cancer.
PY - 2015/3/30
Y1 - 2015/3/30
N2 - Introduction: The efficacy of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in EGFR mutation-positive non-small-cell lung cancer (NSCLC) patients necessitates accurate, timely testing. Although EGFR mutation testing has been adopted by many laboratories in Asia, data are lacking on the proportion of NSCLC patients tested in each country, and the most commonly used testing methods. Methods: A retrospective survey of records from NSCLC patients tested for EGFR mutations during 2011 was conducted in 11 Asian Pacific countries at 40 sites that routinely performed EGFR mutation testing during that period. Patient records were used to complete an online questionnaire at each site. Results: Of the 22,193 NSCLC patient records surveyed, 31.8% (95% confidence interval: 31.2%-32.5%) were tested for EGFR mutations. The rate of EGFR mutation positivity was 39.6% among the 10,687 cases tested. The majority of samples were biopsy and/or cytology samples (71.4%). DNA sequencing was the most commonly used testing method accounting for 40% and 32.5% of tissue and cytology samples, respectively. A pathology report was available only to 60.0% of the sites, and 47.5% were not members of a Quality Assurance Scheme. Conclusions: In 2011, EGFR mutation testing practices varied widely across Asia. These data provide a reference platform from which to improve the molecular diagnosis of NSCLC, and EGFR mutation testing in particular, in Asia.
AB - Introduction: The efficacy of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in EGFR mutation-positive non-small-cell lung cancer (NSCLC) patients necessitates accurate, timely testing. Although EGFR mutation testing has been adopted by many laboratories in Asia, data are lacking on the proportion of NSCLC patients tested in each country, and the most commonly used testing methods. Methods: A retrospective survey of records from NSCLC patients tested for EGFR mutations during 2011 was conducted in 11 Asian Pacific countries at 40 sites that routinely performed EGFR mutation testing during that period. Patient records were used to complete an online questionnaire at each site. Results: Of the 22,193 NSCLC patient records surveyed, 31.8% (95% confidence interval: 31.2%-32.5%) were tested for EGFR mutations. The rate of EGFR mutation positivity was 39.6% among the 10,687 cases tested. The majority of samples were biopsy and/or cytology samples (71.4%). DNA sequencing was the most commonly used testing method accounting for 40% and 32.5% of tissue and cytology samples, respectively. A pathology report was available only to 60.0% of the sites, and 47.5% were not members of a Quality Assurance Scheme. Conclusions: In 2011, EGFR mutation testing practices varied widely across Asia. These data provide a reference platform from which to improve the molecular diagnosis of NSCLC, and EGFR mutation testing in particular, in Asia.
KW - EGFR mutation
KW - Multicenter
KW - Non-small-cell lung cancer
KW - Survey
KW - Testing
UR - http://www.scopus.com/inward/record.url?scp=84931571793&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84931571793&partnerID=8YFLogxK
U2 - 10.1097/JTO.0000000000000422
DO - 10.1097/JTO.0000000000000422
M3 - Article
C2 - 25376513
AN - SCOPUS:84931571793
SN - 1556-0864
VL - 10
SP - 438
EP - 445
JO - Journal of Thoracic Oncology
JF - Journal of Thoracic Oncology
IS - 3
ER -